Tech Company Financing Transactions
Cognito Therapeutics Funding Round
Cognito Therapeutics closed a $73 million Series B investment round on 3/22/2023. Backers included FoundersX Ventures, Alzheimer's Drug Discovery Foundation and IAG Capital Partners.
Transaction Overview
Company Name
Announced On
3/22/2023
Transaction Type
Venture Equity
Amount
$73,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to advance pivotal study of its non-invasive neuromodulation device, which delivers proprietary gamma frequency light and sound stimulation intended to treat Alzheimer's Disease. In a prior Phase 2 clinical trial, the device demonstrated a significant slowing in functional and cognitive decline in the treatment group, as well as a significant decline in brain atrophy over a six-month period. To further demonstrate the efficacy of the device, Cognito is currently enrolling patients in its pivotal clinical trial HOPE for Alzheimer's Disease, across approximately 50 clinical centers in the United States with a target enrollment of 500 patients.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
1218 Massachusetts Ave 200
Cambridge, MA 02138
USA
Cambridge, MA 02138
USA
Phone
Website
Email Address
Overview
Cognito Therapeutics is advancing the field of neuromodulation to create novel therapeutics that improve the lives of patients living with neurodegenerative diseases.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 3/22/2023: Piclo venture capital transaction
Next: 3/22/2023: RiseKit venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs